WO2007023226A3 - Utilisation d'un symbiotique pour le traitement de la dermatite atopique - Google Patents

Utilisation d'un symbiotique pour le traitement de la dermatite atopique Download PDF

Info

Publication number
WO2007023226A3
WO2007023226A3 PCT/FR2006/001979 FR2006001979W WO2007023226A3 WO 2007023226 A3 WO2007023226 A3 WO 2007023226A3 FR 2006001979 W FR2006001979 W FR 2006001979W WO 2007023226 A3 WO2007023226 A3 WO 2007023226A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactose
bacterium
atopic dermatitis
treatment
symbiotic
Prior art date
Application number
PCT/FR2006/001979
Other languages
English (en)
Other versions
WO2007023226A2 (fr
Inventor
Gerard Lacoste
Hubert Desjonqueres
Stephane Patrier
Original Assignee
Lyoct Lab
Gerard Lacoste
Hubert Desjonqueres
Stephane Patrier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyoct Lab, Gerard Lacoste, Hubert Desjonqueres, Stephane Patrier filed Critical Lyoct Lab
Priority to US11/991,046 priority Critical patent/US20090169531A1/en
Priority to CA002620099A priority patent/CA2620099A1/fr
Priority to JP2008527485A priority patent/JP2009506016A/ja
Priority to EP06794353A priority patent/EP1916911A2/fr
Publication of WO2007023226A2 publication Critical patent/WO2007023226A2/fr
Publication of WO2007023226A3 publication Critical patent/WO2007023226A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'un produit comprenant une bactérie Lactobacillus rhamnosus, sous forme vivante, en association avec du lactose, en particulier en association avec un milieu à base de lactose, pour la fabrication d'un médicament ou d'un complément alimentaire pour traiter un patient atteint de dermatite atopique, où ladite bactérie est capable de fermenter le lactose. Selon des modes de réalisation préférés, la bactérie utilisée provient de la souche Lactobacillus rhamnosus Lcr35, elle est utilisée comme probiotique, en association avec un prébiotique à base notamment de lactose, et d'éventuels métabolites résultant de la fermentation de la bactérie sur son milieu de culture, pour traiter la dermatite atopique chez des enfants.
PCT/FR2006/001979 2005-08-25 2006-08-24 Utilisation d'un symbiotique pour le traitement de la dermatite atopique WO2007023226A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/991,046 US20090169531A1 (en) 2005-08-25 2006-08-24 Use of symbiotic for the treatment of atopic dermatitis
CA002620099A CA2620099A1 (fr) 2005-08-25 2006-08-24 Utilisation d'un symbiotique pour le traitement de la dermatite atopique
JP2008527485A JP2009506016A (ja) 2005-08-25 2006-08-24 アトピー性皮膚炎の治療のためのシンバイオティック（ｓｙｍｂｉｏｔｉｃ）の使用
EP06794353A EP1916911A2 (fr) 2005-08-25 2006-08-24 Utilisation d'un symbiotique pour le traitement de la dermatite atopique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508751A FR2889958A1 (fr) 2005-08-25 2005-08-25 Utilisation d'un symbiotique pour le traitement de la dermatite atopique
FR0508751 2005-08-25

Publications (2)

Publication Number Publication Date
WO2007023226A2 WO2007023226A2 (fr) 2007-03-01
WO2007023226A3 true WO2007023226A3 (fr) 2007-06-21

Family

ID=36215634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001979 WO2007023226A2 (fr) 2005-08-25 2006-08-24 Utilisation d'un symbiotique pour le traitement de la dermatite atopique

Country Status (6)

Country Link
US (1) US20090169531A1 (fr)
EP (1) EP1916911A2 (fr)
JP (1) JP2009506016A (fr)
CA (1) CA2620099A1 (fr)
FR (1) FR2889958A1 (fr)
WO (1) WO2007023226A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029702B2 (en) 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
FR2917623B1 (fr) * 2007-06-22 2009-10-09 Lyoct Sa Lab Utilisation d'un probiotique pour la prevention des infections des voies respiratoires
US20100273239A1 (en) * 2007-06-27 2010-10-28 Benedicte Flambard Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis
US20110034371A1 (en) * 2009-08-06 2011-02-10 Kou-Cheng Peng L. casei rhamnosus secreted factors and use thereof
KR101226758B1 (ko) * 2010-09-28 2013-01-25 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
WO2013130773A2 (fr) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions de microbiota et leurs procédés associés
KR20170005093A (ko) * 2014-05-12 2017-01-11 바이오위시 테크놀로지스, 인크. 인간 건강 및 영양 향상을 위한 조성물 및 방법
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
JP6529835B2 (ja) * 2015-06-23 2019-06-12 株式会社フィス 樹状細胞活性化剤
KR101788544B1 (ko) * 2015-11-24 2017-10-23 코스맥스 주식회사 복합 유산균 배양물을 함유하는 피부장벽 강화용 화장료 조성물
CA3073838A1 (fr) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methodes et compositions pour le traitement de troubles associes au microbiome
WO2019232026A1 (fr) 2018-05-29 2019-12-05 BiOWiSH Technologies, Inc. Compositions et procédés pour améliorer la capacité de survie d'animaux aquatiques
WO2021138599A1 (fr) * 2020-01-03 2021-07-08 Forte Subsidiary, Inc. Compositions cosmétiques
FR3110424B1 (fr) * 2020-05-19 2023-10-06 Aime Inc Complément alimentaire comprenant des bactéries lactiques et des extraits de Reishi
IT202000018901A1 (it) * 2020-07-31 2022-01-31 Synbalance Srl Composizioni probiotiche e loro uso nella prevenzione e/o nel trattamento di patologie e/o disturbi della pelle

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CROSS M L ET AL: "Anti-allergy properties of fermented foods: an important immunoregulatory mechanism of lactic acid bacteria?", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 5, May 2001 (2001-05-01), pages 891 - 900, XP002993764, ISSN: 1567-5769 *
DE CHAMPS CHRISTOPHE ET AL: "Persistence of colonization of intestinal mucosa by a probiotic strain, Lactobacillus casei subsp. rhamnosus Lcr35, after oral consumption.", JOURNAL OF CLINICAL MICROBIOLOGY. MAR 2003, vol. 41, no. 3, March 2003 (2003-03-01), pages 1270 - 1273, XP002379338, ISSN: 0095-1137 *
ISOLAURI E ET AL: "PROBIOTICS IN THE MANAGEMENT OF ATOPIC ECZEMA", CLINICAL AND EXPERIMENTAL ALLERGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, vol. 30, November 2000 (2000-11-01), pages 1604 - 1610, XP001064231, ISSN: 0954-7894 *
KALLIOMAKI ET AL: "Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 357, no. 9262, 7 April 2001 (2001-04-07), pages 1076 - 1079, XP005061313, ISSN: 0140-6736 *
MONERET-VAUTRIN D A ET AL: "Probiotics may be unsafe in infants allergic to cow's milk.", ALLERGY. APR 2006, vol. 61, no. 4, April 2006 (2006-04-01), pages 507 - 508, XP002379337, ISSN: 0105-4538 *
PASSERON T ET AL: "Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years.", ALLERGY. APR 2006, vol. 61, no. 4, April 2006 (2006-04-01), pages 431 - 437, XP002379336, ISSN: 0105-4538 *
R. TOJO SIERRA, R. LEIS TRABAZO: "Alimentos funcionales. Su papel en la nutricion preventiva y curativa", BOL PEDIATR, vol. 43, no. 186, 2003, pages 376 - 395, XP002379339 *
SZILAGYI ANDREW: "Redefining lactose as a conditional prebiotic.", CANADIAN JOURNAL OF GASTROENTEROLOGY = JOURNAL CANADIEN DE GASTROENTEROLOGIE. MAR 2004, vol. 18, no. 3, March 2004 (2004-03-01), pages 163 - 167, XP009066052, ISSN: 0835-7900 *
THIERRY PASSERON, JEAN-PHILIPPE LACOUR: "Effects of probiotics on atopic dermatitis", 31 May 2005 (2005-05-31), XP002379335, Retrieved from the Internet <URL:http://adc.bmjjournals.com/cgi/eletters/adc.2004.060673v1> [retrieved on 20060503] *
WESTON S ET AL: "Effects of probiotics on atopic dermatitis: a randomised controlled trial", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 90, no. 9, 29 April 2005 (2005-04-29), online publication, pages 892 - 897, XP009066050, ISSN: 0003-9888 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use

Also Published As

Publication number Publication date
FR2889958A1 (fr) 2007-03-02
CA2620099A1 (fr) 2007-03-01
EP1916911A2 (fr) 2008-05-07
JP2009506016A (ja) 2009-02-12
US20090169531A1 (en) 2009-07-02
WO2007023226A2 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007023226A3 (fr) Utilisation d&#39;un symbiotique pour le traitement de la dermatite atopique
Kechagia et al. Health benefits of probiotics: a review
WO2007085970A3 (fr) Emploi d&#39;une souche de micro-organisme dans le traitement des troubles ponderaux
Sadeghi-Aliabadi et al. Effects of Lactobacillus plantarum A7 with probiotic potential on colon cancer and normal cells proliferation in comparison with a commercial strain
Donkor et al. α-Galactosidase and proteolytic activities of selected probiotic and dairy cultures in fermented soymilk
Sanchez et al. Probiotic fermented milks: present and future
EP4257194A3 (fr) Utilisation de communautés microbiennes pour la santé humaine et animale
Konkit et al. Activities of amylase, proteinase, and lipase enzymes from Lactococcus chungangensis and its application in dairy products
MX2011012069A (es) Micro-organismos no-replicantes y su efecto inmuno estimulador.
WO2002060276A8 (fr) Combinaison de probiotiques
NZ598751A (en) Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance (bifidobacterium breve mcc1274 (ferm bpp-11175))
HK1090289A1 (en) Antiallergic composition
WO2003080813A3 (fr) Souches de lactobacille
WO2008078387A1 (fr) Lait fermenté destiné à améliorer et/ou à traiter la peau et son procédé de production
UA111715C2 (uk) Композиція, що містить пробіотичні бактерії для застосування у лікуванні імунних розладів
EA200800913A1 (ru) Влияние пробиотиков на метаболизм жиров и на ожирение
Nunpan et al. Effect of Prebiotics‐Enhanced Probiotics on the Growth of Streptococcus mutans
WO2011050426A3 (fr) Nouvelles souches de bactérie de l&#39;acide lactique et leurs combinaisons pour la fabrication de préparations probiotiques
WO2007015132A3 (fr) Utilisation de bacteries lactiques specifiques pour la preparation de compositions immunomodulatrices
CA2710820A1 (fr) Procede de production de lait fermente
WO2008002484A3 (fr) Nouvelle souche de lactobacillus bulgaricus et compositions la contenant
ATE536102T1 (de) Probiotischer stamm von lactobacillus delbrueckii subsp bulgaricus
WO2012021016A3 (fr) Souche de lactobacillus ayant une activité anticancéreuse et une composition d&#39;activité anticancéreuse comprenant celle-ci en tant que substance active
GEU20061256Y (en) Yoghurt
Elhami Rad et al. Optimization of Production Conditions of Soy Milk GABA Produced by Probiotic Bacteria.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006794353

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2620099

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008527485

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006794353

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11991046

Country of ref document: US